Multicenter randomized phase II study comparing alternate-day oral therapy using S-1 with the standard regimen as a first-line treatment for patients with locally advanced and metastatic pancreatic cancer: PAN-01 study.

Interim safety analysis of a randomized phase II trial comparing alternate-day oral therapy using S-1 with the standard regimen as a first-line treatment for patients with advanced pancreatic cancer

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.e15267 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. e15267-e15267

Author(s):

Hiroaki Yanagimoto ◽

Takuji Okusaka ◽

Hiroshi Ishii ◽

Junji Furuse ◽

Shinichi Ohkawa ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Oral Therapy ◽

Phase Ii Trial ◽

Advanced Pancreatic Cancer ◽

Line Treatment ◽

First Line ◽

Standard Regimen ◽

Randomized Phase Ii ◽

PACTO: A single center, randomized, phase II study of the combination of nab-paclitaxel and gemcitabine with or without tocilizumab, an IL-6R inhibitor, as first-line treatment in patients with locally advanced or metastatic pancreatic cancer

Annals of Oncology ◽

10.1093/annonc/mdx369.158 ◽

2017 ◽

Vol 28 ◽

pp. v266

Author(s):

I. Chen ◽

J.S. Johansen ◽

T.A. Zimmers ◽

C. Dehlendorff ◽

V. Kirk Parner ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Locally Advanced ◽

Line Treatment ◽

Single Center ◽

First Line ◽

Randomized Phase Ii ◽

Capecitabine (X) plus gemcitabine (G) as first-line treatment in patients (pts) with locally advanced/metastatic pancreatic cancer: an open-label, multicenter phase II study

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.4141 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 4141-4141 ◽

Cited By ~ 1

Author(s):

H.-S. Song ◽

Y.-R. Do ◽

H.-M. Chang ◽

K.-H. Lee ◽

Y.-H. Kim ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Multicenter Phase ◽

P-036 Phase II study of gemcitabine and curcumin as first line treatment for locally advanced or metastatic pancreatic cancer: preliminary data

Annals of Oncology ◽

10.1093/annonc/mdv233.36 ◽

2015 ◽

Vol 26 ◽

pp. iv10

Author(s):

C. Soldà ◽

R. Bardini ◽

C. Sperti ◽

G. Da Dalt ◽

M. Gion ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Preliminary Data ◽

Phase Ii Study ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Phase II study of Gemcitabine and Curcumin (Meriva®) as first line treatment for locally advanced or metastatic pancreatic cancer: preliminary results

Annals of Oncology ◽

10.1093/annonc/mdv344.41 ◽

2015 ◽

Vol 26 ◽

pp. vi102 ◽

Cited By ~ 1

Author(s):

C. Soldà ◽

R. Bardini ◽

C. Sperti ◽

G. Da Dalt ◽

M. Gion ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Preliminary Results ◽

A Randomized Phase II Trial of Pemetrexed plus Irinotecan (ALIRI) versus Leucovorin-Modulated 5-FU plus Irinotecan (FOLFIRI) in First-Line Treatment of Locally Advanced or Metastatic Colorectal Cancer

Oncology ◽

10.1159/000120626 ◽

2007 ◽

Vol 73 (1-2) ◽

pp. 9-20 ◽

Cited By ~ 11

Author(s):

Craig Underhill ◽

David Goldstein ◽

Vera A. Gorbounova ◽

Mikhail Y. Biakhov ◽

Igor S. Bazin ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18)

10.1158/1538-7445.am2014-ct101 ◽

2014 ◽

Cited By ~ 23

Author(s):

Richard S. Finn ◽

John P. Crown ◽

Istvan Lang ◽

Katalin Boer ◽

Igor M. Bondarenko ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Breast ◽

Line Treatment ◽

Cyclin Dependent Kinase ◽

First Line ◽

Randomized Phase Ii ◽

Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G

Annals of Oncology ◽

10.1093/annonc/mdy281.151 ◽

2018 ◽

Vol 29 ◽

pp. viii201

Author(s):

Y. Kito ◽

T. Yamada ◽

T. Matsumoto ◽

H. Yasui ◽

K. Murata ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial

Annals of Oncology ◽

10.1093/annonc/mdx772 ◽

2018 ◽

Vol 29 (3) ◽

pp. 661-668 ◽

Cited By ~ 1

Author(s):

A. Gennari ◽

Z. Sun ◽

U. Hasler-Strub ◽

M. Colleoni ◽

M.J. Kennedy ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Maintenance Schedules ◽

Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-008-0873-9 ◽

2008 ◽

Vol 64 (2) ◽

pp. 317-325 ◽

Cited By ~ 11

Author(s):

Kyung Hee Lee ◽

Min Kyoung Kim ◽

Yeol Hong Kim ◽

Baek Yeol Ryoo ◽

Ho Yeong Lim ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Pancreatic Cancer ◽

Line Treatment ◽

First Line ◽

Multicenter Phase ◽